Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: Effect of post-transplant G-CSF treatment

Journal of Theoretical Biology

Volumn 231, Issue 1, 2004, Pages 69-83

  Østby, Ivar ^a   Kvalheim, Gunnar ^a   Rusten, Leiv S ^c   Grøttum, Per ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Sykehuset Buskerud HF   (Norway)

Author keywords

BN band nucleated granulocyte; CD34+ cluster of differentiation 34 positive; CFU GM colony forming unit granulocyte macrophage; G CSF granulocyte colony stimulating factor; GTRB granulocyte turnover rate from bone marrow to blood

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

NUMERICAL MODEL;

ARTICLE; BREAST CANCER; CALCULATION; CANCER CHEMOTHERAPY; CELL COUNT; COLONY FORMING UNIT; CORRELATION ANALYSIS; GRANULOCYTE; INFUSION; LYMPHOMA; MATHEMATICAL MODEL; MEMBRANE RECONSTITUTION; NEUTROPHIL; OBSERVATION; PREDICTION; PRIORITY JOURNAL; PURIFICATION; STEM CELL MOBILIZATION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MODELS, BIOLOGICAL; NEUTROPHILS;

EID: 4444249441     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtbi.2004.05.010     Document Type: Article

References (48)

1. Basu S., Hodgson G., Katz M., Dunn A.R. Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood. 100(3):2002;854-861
2. Benestad H.B., Rytömaa T. Regulation of maturation rate of mouse granulocytes. Cell Tissue Kinet. 10:1977;461-468
3. Bensinger W.-I., Longin K., Appelbaum F., et al. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF). an analysis of factors correlating with the tempo of engraftment after transplantation Br. J. Haematol. 87:1994;825-831
4. Blystad A.K., Holte H., Kvaløy S., Smeland E., Delabie J., Kvalheim G. High-dose therapy in patients with Hodgkin's disease. the use of selected CD34+ cells is as safe as unmanipulated peripheral progenitor cells (PBPC) Bone Marrow Transpl. 28:2001;849-857
5. Bolwell B.J., Goormastic M., Dannley R., et al. G-CSF post-autologous progenitor cell transplantation. a randomized study of 5,10 and 16 μg/kg/day Bone Marrow Transpl. 19:1997;215-219
6. Bolwell B.J., Pohlman B., Andresen S., et al. Delayed G-CSF after autologous progenitor cell transplantation. a prospective randomized trial Bone Marrow Transpl. 21:1998;369-373
7. Coiffer B., Philip T., Burnett A.K., Symann M.L. Concensus on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies. Ann. Oncol. (Lyon). 5:1993;19-23
8. Cortelazzo S., Viero P., Bellavita P., Rossi A., et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J. Clin. Oncol. 13(4):1995;935-941
9. Cortelazzo S., Rambaldi A., Barbui T. In reply, J. Clin. Oncol. 13(8):1995;2144
10. Dercksen M.-W., Rodenhuis S., Dirkson M.-K.-A., et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J. Clin. Oncol. 13:1995;1922-1932
11. Fermand J.P., Levy Y., Gerota J., et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 73:1989;20-23
12. Gregory S.H., Wing E.J. Neutrophil-Kupffer cell interaction. a critical component of host defenses to systemic bacterial infections J. Leuk. Biol. 72:2002;239-248
13. Haylock D.N., To L.B., Dowse T.L., et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood. 80:1992;1405-1412
14. Kearns M., Wang W.C., Stute N., et al. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J. Pediatrics. 123(3):1993;471-479
15. Kessinger A., Armitage J.O. The evolving role of autologous peripheral stem cell transplantation following high-dose chemotherapy for malignancies. Blood. 77:1991;77-101
16. Klumpp T.R., Mangan K.F., Goldberg S.L., et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation. a prospective, randomized trial J. Clin. Oncol. 13(6):1995;1323-1327
17. Kuwabara T., Kato Y., Kobayashi S., Suzuki H., Sugiyama Y. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim). species differences among rats, monkeys and humans J. Pharmacol. Exp. Therap. 271(3):1994;1535-1543
18. Kuwabara T., Uchimura T., Kobayashi H., et al. Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. Am. J. Physiol. 269(1 Pt 1):1995;E1-E9
19. Kvalheim G. Clinical use of enriched CD34+ cells. Blood Therapies in Medicine. 2:2002;57-64
20. Leibundgut K., von Rohr A., Brülhart K., et al. The number of circulating CD34+ blood cells predicts the colony-forming capacity of leukapheresis products in children. Bone Marrow Transpl. 15:1995;25-31
21. Lill M.C., Lynch M., Fraser J.K., et al. Production of functional myeloid cells from CD34+-selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system. Stem Cells. 12:1994;626-637
22. Lindman, H., Wiklund, T., Holte, H., Ljungman, P., Blomqvist, C., Kvalheim, G., Bengtsson, M., Höglund, M., Wilking, N., the SB6 9401 Study Group, Bergh, J., 1999. FEC mobilized stem cells for high-dose therapy in breast cancer patients. Acta Oncol. 38(2), 239-245.
23. Mary J.Y. Normal human granulopoiesis revisited. I. Blood data. Biomed. Pharmacotherapy. 38:1984;33-43
24. Messner H.A., Curtis J.E., Minden M.D., et al. Clonogenic hemopoietic precursors in bone marrow transplantation. Blood. 70:1987;1425-1432
25. Mukae H., Zamfir D., English D., Hogg J.C., van Eeden S.F. Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor. intravascular behaviour Hemat. J. 1:2000;159-171
26. Niazi S. Textbook of Biopharmaceutics and Clinical Pharmacokinetics. 1979;Appleton-Century-Crofts, New York
27. Østby I., Rusten L.S., Kvalheim G., Grøttum P. A mathematical model for reconstitution of granulopoiesis after high-dose chemotherapy with autologous stem cell transplantation. J. Math. Biol. 47:2003;101-136
28. Petros W.P. Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy. 12(2 Pt 2):1992;32S-38S
29. Price T.H., Chatta G.S., Dale D.C. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 88:1996;335-340
30. Scheding S., Meister B., Baum C., et al. Flt-3 ligand promotes the ex-vivo generation of granulopoietic post-progenitor cells for clinical use after peripheral blood progenitor cell transplantation [abstract]. Exp. Hematol. 25:1997;805
31. Scheding S., Franke H., Diehl V., et al. How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? results of a computer simulation. Exp. Hematol. 27:1999;956-965
32. Sheridan W.P., Morstyn G., Wolf M., et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. The Lancet October. 14:1989;891-895
33. Shi J., Gilbert G.E., Kokubo Y., Ohashi T. Role of the liver in regulating numbers of circulating neutrophils. Blood. 98(4):2001;1226-1230
34. Shimazaki C., Uchiyama H., Fujita N., et al. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. Exp. Hematol. 23:1995;1497-1502
35. Smith S.L., Bender J.G., Maples P.B., et al. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. Exp. Hematol. 10:1993;870-877
36. Spitzer G., Verma D.S., Fisher R., et al. The myeloid progenitor cell - its value in predicting haemapoietic recovery after autologous transplantation. Blood. 55:1980;317-323
37. Spitzer G., Adkins D.R., Spencer V., et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant. neutrophil recovery is improved with modest clinical benefit J. Clin. Oncol. 12(4):1994;661-670
38. Steen R., Tjønnfjord G.E., Grøseth L.A.G., Heldal D., Egeland T. Efflux of CD34+ cells from bone marrow to peripheral blood is selective in steady-state hematopoiesis and during G-CSF administration. J. Hematoth. 6(6):1997;563-573
39. Stute N., Santana V.M., Rodman J.H., Schell M.J., Ihle J.N., Evans W.E. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 79(11):1992;2849-2854
40. Sugiura M., Yamamoto K., Saeada Y., Iga T. Pharmacokinetic/ pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF). comparison between intravenous and subcutaneaous administration Biol. Pharm. Bull. 20(6):1997;684-689
41. Takatani H., Soda H., Fukuda M., et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob. Agents Chemother. 40(4):1996;988-991
42. Tarella C., Castellino C., Locatelli F., et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies. evidence for clinical benefits and reduction of treatment costs Bone Marrow Transpl. 21(4):1998;401-407
43. To, L.B., Dyson, P.G., Juttner, C.A., 1986. Cell dose effect in circulating stem cell autografting (letter). Lancet ii, 404-405.
44. To L.B., Roberts M.M., Haylock D.N., et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transpl. 9:1992;277-284
45. van der Auwera P., Platzer E., Xu Z.-X., et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers. comparison with single and multiple daily doses of filgrastim Am. J. Hematol. 66(4):2001;245-251
46. Vey N., Molnar S., Faucher C., et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation. effect on granulocyte recovery Bone Marrow Transpl. 14:1994;779-782
47. Wang B., Ludden T.M., Cheung E.N., Schwab G.G., Roskos L.K. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J. Pharmacokinet. Pharmacodyn. 28(4):2001;321-342
48. Weaver C.-H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 14:1995;3961-3969